No Detail Found!

Efficacy of 40 mg vs. 80mg daily doses of febuxostat in treating hyperuricemia in chronic kidney disease

Author(s)
Muhammad Sajid Mehmood Department of Physiology, Quetta Institute of Medical Sciences, Quetta, SCM STMU Islamabad, RMU, Rawalpindi, Pakistan; Tehsil Head Quarter Hospital, Gujjar Khan, Northern border University, Arar, KSA
Wajahat Sultan Baig Department of Physiology, Quetta Institute of Medical Sciences, Quetta, SCM STMU Islamabad, RMU, Rawalpindi, Pakistan; Tehsil Head Quarter Hospital, Gujjar Khan, Northern border University, Arar, KSA
Tehreem Aftab Department of Physiology, Quetta Institute of Medical Sciences, Quetta, SCM STMU Islamabad, RMU, Rawalpindi, Pakistan; Tehsil Head Quarter Hospital, Gujjar Khan, Northern border University, Arar, KSA
Umar Kaleem Muhammad Hammad Department of Physiology, Quetta Institute of Medical Sciences, Quetta, SCM STMU Islamabad, RMU, Rawalpindi, Pakistan; Tehsil Head Quarter Hospital, Gujjar Khan, Northern border University, Arar, KSA
Shazia Siddiq Department of Physiology, Quetta Institute of Medical Sciences, Quetta, SCM STMU Islamabad, RMU, Rawalpindi, Pakistan; Tehsil Head Quarter Hospital, Gujjar Khan, Northern border University, Arar, KSA
Abstract
Objective: To compare efficacy of febuxostat 40mg daily with febuxostat 80 mg daily in treating hyperuricemia in patients with chronic kidney disease. Methodology: This comparative multi-centric study was done from 01-01-2018 to 30-06-2018 on 305 patients of chronic renal failure (S. Creatinine 2.1±0.35) and raised serum uric acid levels were included in the study. It was non-probability consecutive sampling. The patients were in range of 18 to 70 years. They were not on dialysis. A total of 151 patients were given febuxostat 40mg OD and 147 were treated with febuxostat 80mg OD for 4 weeks. Serum uric acid levels of more than 7.0mmol/l in males and 6.0mg/dl in females was labelled as hyperuricemia. Serum uric acid levels were estimated at beginning and end of 4 weeks of treatment. Chi-square test was used for comparison between two groups. Results:  The serum uric acid levels decreased in 68.1% of patients. In febuxostat 80mg OD group, 76.2% patients responded to treatment while in febuxostat 40mg OD group 59.2% achieved target uric acid levels (p=0.025). Conclusion:  Febuxostat 80 mg treated hyperuricemia more effectively than febuxostat 40 mg and did not deteriorate renal functioning. 
Publication Details
Page(s) 839-842
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 48, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
Chronic kidney disease, Efficacy, Hyperuricemia, xanthine oxidase inhibitor.
References
Carney EF .2015 .Epidemiology: Global Burden of Disease Study 2013 reports that disability caused by CKD is increasing worldwide. Nature Rev Nephrol, 11 : 446-9.
Richette P,Doherty M,Pascual E,Barskova V,Becce F,Castañeda-Sanabria J .2017 .2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, 76 : 29-42.
Eleftheriadis T,Golphinopoulos S,Pissas G,Stefanidis I. .2017 .Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial. J Adv Res, 8 : 555-60.
Zhu Y,Pandya BJ,Choi HK .2011 .Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum, 63 : 3136-41.
Nan H,Qiao Q,Dong Y,Gao W,Tang B,Qian R .2006 .The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol, 33 : 1346-50.
Rincon-Choles H,Jolly SE,Arrigain S,Konig V,Schold JD,Nakhoul G .2017 .. Impact of Uric Acid Levels on Kidney Disease Progression. Am J Nephrol, 46 : 315-22.
Tsai CW,Lin SY,Kuo CC,Huang CC .2017 .Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. PLoS One, 12 : e0170393.
Kumagai T,Ota T,Tamura Y,Chang WX,Shibata S,Uchida S. .2017 .Time to target uric acid to retard CKD progression. Clin Exp Nephrol, 21 : 182-92.
Sampson AL,Singer RF,Walters GD .2017 .Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev, 10 : CD009460.
Pisano A,Cernaro V,Gembillo G,D'Arrigo G,Buemi M,Bolignano D. Xanthine M .2017 .Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis. Int J Mol Sci, 18 : 2283.
Matsuo H,Ishikawa E,Machida H,Mizutani Y,Tanoue A,Ohnishi T .2020 .Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol, 24 : 307-13.
Kamel B,Graham GG,Williams KM,Pile KD,Day RO .2017 .. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clin Pharmacokinet, 56 : 459-75.
Kimura K,Hosoya T,Uchida S,Inaba M,Makino H,Maruyama S .2018 .Febuxostat Therapy for Patients with Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis, 72 : 798-810.
Liu X,Wang H,Ma R,Shao L,Zhang W,Jiang W .2019 .The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3- 5. Clin Exp Nephrol, 23 : 362-70.
Gunawardhana L,Becker MA,Whelton A,Hunt B,Castillo M .2018 .Saag K. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebocontrolled study. Arthritis Res Ther, 20 : 99.
Rincon-Choles H,Jolly SE,Arrigain S,Konig V,Schold JD,Nakhoul G .2017 .. Impact of Uric Acid Levels on Kidney Disease Progression. Am J Nephrol, 46 : 315-22.
Xia X,Luo Q,Li B,Lin Z,Yu X,Huang F .2016 .Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism, 65 : 1326-41.
Jackson RL,Hunt B,MacDonald PA B .2012 .The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr, 12 : 11-6.
Peng YL,Tain YL,Lee CT,Yang YH,Huang YB,Wen YH .2020 .Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Sci Rep, 10 : 1-1.
Kojima S,Matsui K,Hiramitsu S,Hisatome I,Waki M,Uchiyama K .2019 .Febuxostat for Cerebral and CaRdiorenovascular Events Prevention Study. Eur Heart J, 40 : 1778-86.
Shibagaki Y,Ohno I,Hosoya T,Kimura K .2014 .Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertension Res, 37 : 919-25.
Lin TC,Hung LY,Chen YC,Lo WC,Lin CH,Tam KW .2019 .Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine, 98 : e16311.
Kaewput W,Thongprayoon C,Rangsin R,Ruangkanchanasetr P,Bathini T,Mao MA .2019 .Association between serum uric acid and chronic kidney disease in patients with hypertension: A multicenter nationwide cross-sectional study. J Evid Based Med, 12 : 235-42.
0

Citations

0

Downloads

148

Views